

POLAR3[◇] Total Hip Solution delivers high survivorship at 12 years, greater than class average patient satisfaction and improvements in patient-reported outcome measures (PROMs)¹

Overview

- Bespoke implant report produced by the UK National Joint Registry (NJR) summarising usage and outcomes associated with POLAR3, which is the combination of POLARSTEM[®] Hip Reconstruction System, OXINIUM[®] Technology femoral head, highly cross-linked polyethylene (XLPE) bearing and R3[°] cup¹
- The analysis is based on data collected by the NJR and on PROMs data collected by NHS Digital*
- Reported POLAR3 usage between July 2007 – October 2024 for:
 - 32,859 total hip arthroplasties (THA)
 - 29,510 total patients
 - 579 implanting surgeons at 111 centres

Considerations

*The data used for this analysis was obtained from the NJR Supplier Feedback System. The Healthcare Quality Improvement Partnership (HQIP) and/or the NJR take no responsibility for the accuracy, currency, reliability and correctness of any data used or referred to in this report, nor for the accuracy, currency, reliability and correctness of links or references to other information sources and disclaims all warranties in relation to such data, links and references to the maximum extent permitted by legislation.

Results



97.7%
survivorship with
POLAR3

37%




Lower revision risk with POLAR3 compared to class average for all other THA with cementless stems at 12 years

ODEP²

10A* POLARSTEM Cementless Stem
15A* R3 HA Cementless Cup
10A R3 non-HA Cementless Cup

Patients who received POLAR3...

Were **significantly more likely to be satisfied** with their THA and to consider their procedure a success (Chi-squared; $p < 0.001$), after 6 months, compared to those who received all other THA with cementless stems



Achieved **significantly better average 6-month PROM scores** compared to patients who received all other THA with cementless stems ($p < 0.001$)

PROMs	POLAR3	Class average [†]	p value
Oxford Hip Score	23.1 (22.9–23.3)	21.7 (21.7–21.8)	$p < 0.001$
EQ-5D	0.473 (0.467–0.479)	0.444 (0.443–0.445)	
EQ-VAS	14.8 (14.4–15.2)	12.5 (12.4–12.6)	

[†]All other THA with cementless stems.

Adjusted health gain scores (95% confidence interval) at 6 months after THA. Adjusted scores correspond to the NHS Digital version 3 case-mix-adjustment model. Using case-mix adjusted scores allows for a more accurate comparison between groups by taking into account variations in patient characteristics.

Conclusions

POLAR3 delivers 12-year survivorship of 97.7% and also delivers significantly higher patient satisfaction, success outcomes and improvements in PROMs compared to the class average for cementless stems in all other THA patients.

Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Smith+Nephew representative or distributor if you have questions about the availability of Smith+Nephew products in your area. For detailed product information, including indications for use, contraindications, precautions and warnings, please consult the product's applicable Instructions for Use (IFU) prior to use.

References:
1. National Joint Registry for England, Wales and Northern Ireland: POLARSTEM Cementless (OXINIUM/XLPE/R3 cup) bespoke implant summary report. 17 November 2024. Copy available upon request. 2. Orthopaedic Data Evaluation Panel (ODEP). Available at: <http://www.odep.org.uk>. Accessed June 12, 2025.